OBJECTIVES: There is controversy about whether 3- or 6-month molecular assessment predicts progression-free and overall survival in those with @entity1860 ( @entity1860 ). The factors predicting molecular response at 3, 6, and 12 months have not been studied extensively. The study objective was to study the factors affecting molecular response at 3 and 6 months in @entity1 with @entity1860 who are receiving @entity2213 mesylate. METHODS: We prospectively enrolled @entity1 with newly diagnosed @entity1860 who were receiving @entity2213 as the initial therapy for @entity1860 . The diagnosis of @entity1860 was based on clinical examination, bone marrow, and demonstration of @entity1861 (IS) transcripts by polymerase chain reaction. The molecular response(IS) was assessed at 3, 6, and 12 months by GeneXpert (Cepheid, Sunnyvale, CA) and co-related with various baseline characteristics of @entity1 . We also looked at whether early achievement of a complete hematologic response within 6 weeks predicts molecular response at 3 or 6 months. The study took place at a tertiary care hospital in Northwest India catering to @entity1 belonging to low-middle socioeconomic status. RESULTS: We enrolled 131 @entity1 with @entity1860 in the chronic phase from July 1, 2013, to August 31, 2014. The median age of the @entity1 was 40 years (range, 13-67) with a male preponderance (61% were male). Most @entity1 presented with symptoms of low-grade fever (52.7%) and abdominal fullness (26.7%). Spleen was palpable in 84.7% of @entity1 . The median hemoglobin at presentation was 10.8 g/dL (range, 4.8-18.4 g/dL), white cell count was 138.3  * 10(9)/L (4.1-697  * 10(9)/L), and platelet count was 326  * 10(9)/L (85-1819  * 10(9)/L). The median number of peripheral blood basophils was 3% (range, 0%-20%), and blasts were 3% (range, 0%-10%). @entity4018 of more than grade 1 was present in 30% of @entity1 . Most @entity1 belonged to intermediate Sokal (45.8%) and Hasford (55%) scores and low EUropean Treatment Outcome Study (78.6%) score. Of 128 evaluable @entity1 at 3 months, 96.9% achieved @entity1503 ( @entity1503 ) and 82.3% achieved @entity1861 (IS) of less than 10%. None of the @entity1 who had @entity1861 (IS) > 10% at 3 months achieved @entity1861 (IS)  < 1% at 6 months or  < 0.1% at 12 months. Early achievement of @entity1503 (<  6  weeks), peripheral blood blast count of  < 5%, and @entity880 dehydrogenase  < 851 U/L were significantly associated with achievement of @entity1861 (IS)  < 10% at 3 months and @entity1861 (IS)  < 1% at 6 months. CONCLUSIONS: We found that @entity1861 (IS) assessment at 3 months is superior to assessment at 6 months. @entity1 with @entity1860 in the chronic phase who achieve @entity1503 within 6 weeks are more likely to achieve @entity1861 (IS)  < 10% at 3 months and  < 1% at 6 months than @entity1 who achieve @entity1503 between 7 and 12 weeks.

Factors Affecting Early Molecular Response in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity1861 :: ('25', 'Gene') :: ['BCR ABL'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['complete hematologic remission', 'CHR'] @entity4018 :: ('MESH:D055728', 'Disease') :: ['Myelofibrosis'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib', 'imatinib mesylate']
@entity1860 :: (MESH:D015464,Disease) :: ['Chronic Myeloid Leukemia']
